Research Spotlight by Dr. Anna Berkenblit: May 2025

Editor's note: The "Research Spotlight" series is written by Dr. Anna Berkenblit, PanCAN's Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and research in pancreatic cancer. Follow Dr. Berkenblit on X and LinkedIn.

Progress for Pancreatic Cancer Continues to Lag: The Urgent Need for Action

Each year, the National Cancer Institute (NCI) shares critical updates on the state of cancer in the United States. In the latest Annual Report to the Nation on the Status of Cancer, there is good news as overall cancer incidence and death rates are continuing to decline representing changes in risk factors, increases in screening utilization, and advances in treatment. Unfortunately, that is not the case for pancreatic cancer. Pancreatic cancer incidence and death rates continue to climb. According to data, between 2017-2021, pancreatic cancer incidence increased for both men and women. Death rates, which have declined for many other cancers, remained flat for women and increased for men between 2001-2022. These statistics reveal that pancreatic cancer has not yet benefited from the advances that have transformed care for other cancers.

Pancreatic Cancer and Colorectal Cancer: A Growing Burden

Findings of a cohort study called Incidence of Pancreas and Colorectal Adenocarcinoma in the U.S. were published in JAMA Network Open. The study evaluated incidence of pancreatic adenocarcinoma (the most common type of pancreatic cancer) and colorectal adenocarcinoma in the U.S. over time. The authors' findings suggest that incidence rates of pancreatic adenocarcinoma are rising across all age groups, while colorectal adenocarcinoma rates are increasing among younger adults (under 50). Data from PanCAN and colleagues show that by 2030, pancreatic cancer is projected to surpass colorectal cancer as the second leading cause of cancer deaths in the U.S. This shift is largely due to the success of colorectal cancer screening tools like colonoscopies, which allow for early detection and even prevention. Pancreatic cancer does not yet have an effective screening method for the general population, which is why most patients with pancreatic cancer are diagnosed at an advanced stage. That's why we must focus on identifying high-risk individuals, such as those with a family history or genetic predisposition, and encourage their participation in surveillance programs to detect pancreatic cancer earlier.

If you're concerned about your risk for pancreatic cancer, talk to your doctor, or reach out to PanCAN Patient Services to learn more about risk factors and surveillance programs.

Mental Health in Focus: Supporting Caregivers This May

May is Mental Health Awareness Month, and it's the perfect time to recognize an often-overlooked group in cancer care, our caregivers. In a recent study, The psychosocial impact of pancreatic cancer on caregivers, qualitative research underscores the emotional burden faced by caregivers of patients with pancreatic cancer. Caregivers frequently encounter intense emotional strain due to the rapid progression and poor prognosis of pancreatic cancer. This includes managing complex care needs, witnessing patient suffering, and confronting the impending loss of a loved one. Additional secondary stressors of the caregiving role include disruptions in daily routine, employment, and social relationships. Caregivers may experience financial strain, social isolation, and alterations in family dynamics, compounding their stress levels.

PanCAN is committed to supporting caregivers with compassion, resources, and a listening ear. If you're a caregiver, don't carry the emotional load alone. Call our Patient Services team today for information on support to connect with mental health professionals who have experience working with families impacted by cancer.

Final Thoughts: A Call for Equity, Research, and Compassion

Pancreatic cancer remains a leading cause of cancer death, with rising rates and limited tools for early detection. It is time to act and continue advocating for investment in cancer research to save lives. Recently, President Trump released his FY26 budget that includes a proposed $17.5 billion or a 37% cut to the National Institutes of Health (NIH), which includes the NCI. This astounding reduction will have a destructive impact on progress for pancreatic cancer. At a time when we should be pushing research forward, these cuts will take us backward, jeopardizing the lives of patients today and in the future. Contact your members of Congress and urge them to protect cancer research funding because patients with pancreatic cancer can't afford to wait.